NASDAQ
06.02.26 | 21:59
0,815 US-Dollar
+1,88 % +0,015
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TELA BIO Aktie jetzt für 0€ handeln | |||||
| 23.01. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 3 | GlobeNewswire (USA) | ||
| 23.12.25 | BD faces hernia mesh lawsuit from Tela Bio | 7 | MassDevice | ||
| 23.12.25 | Small Medtech TELA Bio Takes On Becton Dickinson, Alleges Hernia Mesh Monopoly | 4 | Benzinga.com | ||
| 12.12.25 | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 4 | GlobeNewswire (USA) | ||
| 01.12.25 | TELA Bio stock price target lowered to $3 by Lake Street on sales issues | 1 | Investing.com | ||
| 17.11.25 | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 14.11.25 | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.11.25 | These Analysts Cut Their Forecasts On TELA Bio After Q3 Earnings | 1 | Benzinga.com | ||
| 14.11.25 | Piper Sandler lowers TELA Bio stock price target to $1.25 on soft Q3 results | 1 | Investing.com | ||
| 14.11.25 | TELA Bio stock price target lowered to $5 at Citizens on lower ASP | 1 | Investing.com | ||
| 14.11.25 | Tela Bio outlines at least 16% 2025 revenue growth target while strengthening commercial team and balance sheet | 1 | Seeking Alpha | ||
| 13.11.25 | Earnings call transcript: Tela Bio Q3 2025 sees revenue growth but EPS miss | 1 | Investing.com Deutsch | ||
| 13.11.25 | TELA Bio prices $13 million offering of common stock and warrants | 1 | Investing.com | ||
| 13.11.25 | TELA Bio prices $13M registered direct offering of common stock, pre-funded warrants | 2 | Seeking Alpha | ||
| 13.11.25 | TELA Bio, Inc.: TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants | 3 | GlobeNewswire (USA) | ||
| 13.11.25 | TELA Bio meldet 9 % Umsatzwachstum im 3. Quartal und passt Prognose für 2025 an | 1 | Investing.com Deutsch | ||
| 13.11.25 | TELA Bio GAAP EPS of -$0.19 beats by $0.02, revenue of $20.7M misses by $1.08M | 6 | Seeking Alpha | ||
| 13.11.25 | TELA Bio, Inc.: TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility | 151 | GlobeNewswire (Europe) | MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 04.11.25 | TELA Bio, Inc.: TELA Bio to Announce Third Quarter 2025 Financial Results | 2 | GlobeNewswire (USA) | ||
| 03.11.25 | TELA Bio beruft William Plovanic in den Verwaltungsrat | 2 | Investing.com Deutsch |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 34,650 | -0,07 % | Arbutus jumps on ruling in patent dispute with Moderna | ||
| SAREPTA THERAPEUTICS | 15,680 | +0,16 % | Sarepta gets New Zealand approval for Huntington's disease trial | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,568 | +2,10 % | PacBio Completes Sale of Short-Read Sequencing Assets | MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of... ► Artikel lesen | |
| MYRIAD GENETICS | 4,340 | 0,00 % | Myriad Genetics, Inc.: Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance | SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 0,920 | +7,39 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference | King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 4,826 | +0,88 % | SD-Tipp CytomX: Was tun nach +1.438% in 10 Monaten? | Unsere Aktien-Empfehlung CytomX Therapeutics erlebt derzeit einen außergewöhnlich starken Kursverlauf. Innerhalb kurzer Zeit hat sich das Papier von einem lange übersehenen Small-Cap-Titel zu einem... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,180 | +3,76 % | EQS-News: Norgine Pharmaceuticals Limited: Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology | EQS-News: Norgine Pharmaceuticals Limited
/ Schlagwort(e): Produkteinführung/Vereinbarung
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung... ► Artikel lesen | |
| RAPT THERAPEUTICS | 48,000 | 0,00 % | Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals | LONDON (dpa-AFX) - This week's biotech landscape was shaped by workforce restructuring, high-profile acquisitions, and clinical trial data readouts across key therapeutic areas such as ovarian... ► Artikel lesen | |
| TC BIOPHARM | 0,825 | 0,00 % | TC BioPharm plc - 15-12G, Securities registration termination | ||
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Qiagen übertrifft Markterwartungen im vierten Quartal | DJ Qiagen übertrifft Markterwartungen im vierten Quartal
DOW JONES--Qiagen hat im Schlussquartal 2025 den Umsatz gesteigert, der operative Gewinn ging gegenüber dem Vorjahr zurück. 2026 rechnet... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen |
Das Unternehmen TELA BIO INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,015 (+1,88 %) liegt der Kurs bei 0,815 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELA BIO INC finden Sie auf Wallstreet Online.